Cargando…

Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma

BACKGROUND: NLR, PLR, and LMR have been associated with pancreatic ductal adenocarcinoma (PDAC) survival. Prognostic value and optimal cutpoints were evaluated to identify underlying significance in surgical PDAC patients. METHODS: NLR, PLR, and LMR preoperative values were available for 277 PDAC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pointer, David T., Roife, David, Powers, Benjamin D., Murimwa, Gilbert, Elessawy, Sameh, Thompson, Zachary J., Schell, Michael J., Hodul, Pamela J., Pimiento, Jose M., Fleming, Jason B., Malafa, Mokenge P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422564/
https://www.ncbi.nlm.nih.gov/pubmed/32782024
http://dx.doi.org/10.1186/s12885-020-07182-9
_version_ 1783570029491519488
author Pointer, David T.
Roife, David
Powers, Benjamin D.
Murimwa, Gilbert
Elessawy, Sameh
Thompson, Zachary J.
Schell, Michael J.
Hodul, Pamela J.
Pimiento, Jose M.
Fleming, Jason B.
Malafa, Mokenge P.
author_facet Pointer, David T.
Roife, David
Powers, Benjamin D.
Murimwa, Gilbert
Elessawy, Sameh
Thompson, Zachary J.
Schell, Michael J.
Hodul, Pamela J.
Pimiento, Jose M.
Fleming, Jason B.
Malafa, Mokenge P.
author_sort Pointer, David T.
collection PubMed
description BACKGROUND: NLR, PLR, and LMR have been associated with pancreatic ductal adenocarcinoma (PDAC) survival. Prognostic value and optimal cutpoints were evaluated to identify underlying significance in surgical PDAC patients. METHODS: NLR, PLR, and LMR preoperative values were available for 277 PDAC patients who underwent resection between 2007 and 2015. OS, RFS, and survival probability estimates were calculated by univariate, multivariable, and Kaplan-Meier analyses. Continuous and dichotomized ratio analysis determined best-fit cutpoints and assessed ratio components to determine primary drivers. RESULTS: Elevated NLR and PLR and decreased LMR represented 14%, 50%, and 50% of the cohort, respectively. OS (P = .002) and RFS (P = .003) were significantly decreased in resected PDAC patients with NLR ≥5 compared to those with NLR < 5. Optimal prognostic OS and RFS cutpoints for NLR, PLR, and LMR were 4.8, 192.6, and 1.7, respectively. Lymphocytes alone were the primary prognostic driver of NLR, demonstrating identical survival to NLR. CONCLUSIONS: NLR is a significant predictor of OS and RFS, with lymphocytes alone as its primary driver; we identified optimal cutpoints that may direct future investigation of their prognostic value. This study contributes to the growing evidence of immune system influence on outcomes in early-stage pancreatic cancer.
format Online
Article
Text
id pubmed-7422564
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74225642020-08-21 Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma Pointer, David T. Roife, David Powers, Benjamin D. Murimwa, Gilbert Elessawy, Sameh Thompson, Zachary J. Schell, Michael J. Hodul, Pamela J. Pimiento, Jose M. Fleming, Jason B. Malafa, Mokenge P. BMC Cancer Research Article BACKGROUND: NLR, PLR, and LMR have been associated with pancreatic ductal adenocarcinoma (PDAC) survival. Prognostic value and optimal cutpoints were evaluated to identify underlying significance in surgical PDAC patients. METHODS: NLR, PLR, and LMR preoperative values were available for 277 PDAC patients who underwent resection between 2007 and 2015. OS, RFS, and survival probability estimates were calculated by univariate, multivariable, and Kaplan-Meier analyses. Continuous and dichotomized ratio analysis determined best-fit cutpoints and assessed ratio components to determine primary drivers. RESULTS: Elevated NLR and PLR and decreased LMR represented 14%, 50%, and 50% of the cohort, respectively. OS (P = .002) and RFS (P = .003) were significantly decreased in resected PDAC patients with NLR ≥5 compared to those with NLR < 5. Optimal prognostic OS and RFS cutpoints for NLR, PLR, and LMR were 4.8, 192.6, and 1.7, respectively. Lymphocytes alone were the primary prognostic driver of NLR, demonstrating identical survival to NLR. CONCLUSIONS: NLR is a significant predictor of OS and RFS, with lymphocytes alone as its primary driver; we identified optimal cutpoints that may direct future investigation of their prognostic value. This study contributes to the growing evidence of immune system influence on outcomes in early-stage pancreatic cancer. BioMed Central 2020-08-11 /pmc/articles/PMC7422564/ /pubmed/32782024 http://dx.doi.org/10.1186/s12885-020-07182-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Pointer, David T.
Roife, David
Powers, Benjamin D.
Murimwa, Gilbert
Elessawy, Sameh
Thompson, Zachary J.
Schell, Michael J.
Hodul, Pamela J.
Pimiento, Jose M.
Fleming, Jason B.
Malafa, Mokenge P.
Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
title Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
title_full Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
title_fullStr Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
title_full_unstemmed Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
title_short Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
title_sort neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422564/
https://www.ncbi.nlm.nih.gov/pubmed/32782024
http://dx.doi.org/10.1186/s12885-020-07182-9
work_keys_str_mv AT pointerdavidt neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT roifedavid neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT powersbenjamind neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT murimwagilbert neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT elessawysameh neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT thompsonzacharyj neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT schellmichaelj neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT hodulpamelaj neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT pimientojosem neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT flemingjasonb neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma
AT malafamokengep neutrophiltolymphocyterationotplatelettolymphocyteorlymphocytetomonocyteratioispredictiveofpatientsurvivalafterresectionofearlystagepancreaticductaladenocarcinoma